Table 4. Overview of treatment‐emergent adverse events (safety population).
Abbreviations: cFOLFOXIRI‐BEV, concurrent 5‐fluorouracil/leucovorin/oxaliplatin/irinotecan plus bevacizumab; FOLFOX‐BEV, 5‐fluorouracil/leucovorin/oxaliplatin plus bevacizumab; sFOLFOXIRI‐BEV, sequential 5‐fluorouracil/leucovorin/oxaliplatin/irinotecan plus bevacizumab; TEAE, treatment‐emergent adverse event.